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Introduction
For the last 13 years, the Breast Committee of the Arbeits gemeinschaft Gynäkologische Onkologie (German Gyneco logical Oncology Group, AGO) has been preparing and updating evidencebased recommendations for the diagnosis and treatment of patients with early and metastatic breast cancer. The AGO Breast Committee consists of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiological diagnostics, medical oncology, and radiation oncology. This update has been performed according to a documented rulefixed algo rithm, by thoroughly reviewing and scoring chapter by chap ter the recent publications for their scientific validity (Oxford level of evidence (LoE), www.cebm.net [1] ) and clinical rele vance (AGO grades of recommendation (GR); table 1). We present the 2014 update; the full version of the updated slide set is available online as a PDF file in both English and German [2] .
Breast Cancer Risk Factors
Individual risk factors can be classified into nonmodifiable, modifiable, and socially defined factors. Currently, there is good evidence that changes in some modifiable risk factors could substantially decrease the breast cancer risk. This means that every woman could decrease her personal risk of breast cancer by adopting a healthy lifestyle.
With the exception of a total fat intake that might increase the body mass index (BMI) and thus the breast cancer risk, there is no convincing data that the intake of fruits and vege tables, micronutrients, trace elements, or vitamins may reduce the breast cancer risk [3, 4] . However, prevention of diabetes mellitus type II could reduce breast cancer incidence and mortality [5] .
Alcohol use may be more strongly associated with the risk of hormonesensitive breast cancers than of hormoneinsensi tive subtypes, suggesting distinct etiologic pathways for these two breast cancer subtypes [6] .
A systematic review and metaanalysis on the association of oral contraceptives (OC) and risk of ovarian cancer and breast cancer among highrisk women (BRCA mutation carriers) suggest that associations between everuse of OC and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population [7] . screening program. Until now there are no specific treatment options in diseased mutation carriers. Breastconserving surgery (BCS) is safe and the use of platinumbased chemo therapy regimens as well as poly(ADPribose) polymerase (PARP) inhibitors is currently validated in prospective studies.
Breast Cancer Diagnostics
The aim of early detection and screening of breast cancer is to reduce the breast cancer specific mortality and the treat mentdependent morbidity. The detection of invasive breast cancer at an early stage (stage I-IIA) offers the chance to sur vive this disease with less treatment impairment and better quality of life.
Professionals and women need to be informed about the benefits and harms of cancer screening tests before making medical decisions. This includes clear and understandable information in absolute terms about falsepositive rates, false negative rates, overdiagnosis, and overtreatment.
Supplemental breast ultrasound (US) in the population of women with mammographically dense breast tissue (Ameri can College of Radiology (ACR) 3 and 4) permits the detec tion of small, otherwise occult, breast cancers. Potential ad verse impacts on women in the intermediaterisk group are associated with an increased biopsy rate. The arguments against US used as a screening modality alone are lack of re producibility, high falsepositive rate, low positive predictive value (PPV) for biopsy, inability to detect most ductal carci noma in situ (DCIS) cases, operator dependency, and lack of quality assurance.
There are no data to recommend breast US alone or auto mated breast volume scanning (ABVS) as breast cancer screening methods. The recent Cochrane Database System atic Review from 2013 [14] 'did not detect any controlled studies on the use of adjunct ultrasonography for screening in women at average risk for breast cancer. One ongoing rand omized controlled trial was identified ...' That is why 'pres ently, there is no methodologically sound evidence available, justifying the routine use of ultrasonography as an adjunct screening tool in women at average risk for breast cancer. ' For BRCA mutation carriers, an additional (to breast magnetic resonance imaging (MRI) and mammography) semiannual US screening seems to be a sensitive and effec tive method [15, 16] . Elastography is a USbased method and has some advantages in diminishing the rate of Breast Imag
Hereditary Breast Cancer and Prevention
The indication of testing patients for BRCA1/2 mutations is based on family and personal histories of breast and/or ovarian cancer. However, before performing genetic testing, counselling and informed consent is mandatory and should cover the consequences after the detection of a mutation.
A checklist regarding the personal history is available in German (www.aekwl.de/fileadmin/qualitaetssicherung/ Zertifizierungsstelle/FB-erbliche-Belastung-V2013-08-07.pdf).
Of all genetic testing results, 5-30% reveal variants of un known significance (VUS), of which it is not clear if they are causative for disease development [8] . As more than 60% of the VUS are confidential or extremely rare and population specific, only large databases such as the database of the Ger man Consortium of Hereditary Breast and Ovarian Cancer (GCHBOC) allow the classification of most of these VUS. BRCA1 and BRCA2 explain only about 50% of the familial aggregation. Recent data suggest that no further highrisk genes such as BRCA1/2 (odds ratio (OR) > 5.0) exist and that the remaining heritability is due to moderaterisk genes (e.g. RAD51C, ATM, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN; OR 1.5-5.0) and lowrisk variants (FGFR2, TOX3, 2q35, 11q15, SLC4A7, 5p12, MAP3K1; OR < 1.5) that are transmitted via an oligogenetic trait [9] [10] [11] . Lowrisk variants also show associations with specific breast cancer subtypes [12] . RAD51C is a new moderatetohighrisk gene. More over, there are many nonBRCAassociated hereditary cancer syndromes with an increased risk for breast cancer (LiFraumeni, Cowden, hereditary diffuse gastric cancer syn drome, PeutzJeghers syndrome, Lynch syndrome). The use of commercially available but not validated breast cancer gene panels for risk prediction is not recommended outside of controlled clinical trials [13] .
For many of those genetically defined subtypes, issues such as histopathological features, sensitivity to different screening modalities, course of disease, or specific treatment response still remain unclear. Healthy women who are identified as being at moderate to high risk for disease development should be offered participation in a surveillance/screening program. Women with BRCA1/2 mutations should also be offered non directive counselling for the uptake of primary preventive measures (e.g. riskreducing bilateral salpingooophorectomy at around 40 years of age, riskreducing bilateral mastectomy, or medical prevention with tamoxifen, raloxifen, or an aro matase inhibitor) in addition to participation in a surveillance/ ing Report and Data System (BIRADS) III lesions and in measuring the true size of breast cancer lesions [17] . According to a recent metaanalysis, the reexcision rate is not reduced but the initial and total rate of mastectomy is in creased if a preoperative breast MRI is performed compared with no preoperative breast MRI [18, 19] . In case of lobular invasive breast cancer, there is a significant reduction of the reexcision rate and no significant impact on the rate of mas tectomies due to the use of preoperative breast MRI [18, 19] . According to the second metaanalysis of this study group [19] , the preoperative breast MRI does not reduce the rate of local recurrences and does not improve the local recurrence free survival and the distant metastasesfree survival [18] . This is why preoperative breast MRI is not recommended as a routine method for all patients. For some patients, e.g. with high breast density (ACR 3-4) and lobular invasive cancer, it can be considered (LoE 1b, B, AGO ++).
With the use of intraoperative US, the rate of reexcisions, the volume of resection, and the rate of involved margins are significantly reduced according to a randomized study [20] and a recent metaanalysis [21] . That is why intraoperative US can be performed as a method to reduce the reexcision rate and rate of R1 resections (LoE 1a, A, AGO +/-).
If there is a clinical and/or sonographical suspicious axillary lymph node, USguided fine needle aspiration or core cut biopsy may be performed to avoid twostage axillary surgery (LoE 2b, B, AGO +) [22] . The standard procedure in patients with unsuspicious axillary lymph nodes is sentinel node biopsy.
Mammography, breast US, and breast MRI are the pre ferred methods for evaluating the response to neoadjuvant chemotherapy (NACT). Until now, breast MRI seems to be the best method to predict pathologic complete response (pCR) after NACT. According to an indirect comparison be tween MRI and breast US, US seems to have the same sensi tivity and specificity to predict pCR after NACT [21, [23] [24] [25] [26] . Definition standards of response are required. The PPV for predicting pCR ranges around 47-73%, and the negative pre dictive value (NPV) around 71-100%. First results with diffu sionweighted (DW)MRI show that the pretreatment appar ent diffusion coefficient (ADC) is dependent on the tumor subtype [27] .
Up to now, none of the imaging modalities are predictive of pCR.
Pathology
Because of growing evidence that a considerable propor tion of human epidermal growth factor receptor 2 (HER2) positive cases may be overlooked if the testing is primarily based on the ratio of the HER2 gene copy number in relation to centromere 17, a new consensus on HER2 testing was pub lished by the American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) [28] . Accordingly, the AGO guidelines have been revised with some modifica tions in comparison to the published consensus. The essential changes are: -Equivocal cases by in situ hybridization (ISH) are no longer defined by ratio but exclusively by an average copy number of ≥ 4 to < 6 HER2 signals/nucleus. -Even with a ratio < 2, cases can be HER2 positive if ≥ 6 HER2 signals are present. -Cases with an average copy number of ≥ 4 to < 6 HER2 signals/nucleus (equivocal), or < 4 signals but with a ratio ≥ 2, are considered as HER2 positive. -Less than 10% strongly membranestained cells by immu nohistochemistry (IHC) are considered as HER2 2+ (equivocal cases requiring additional testing by ISH). -In rare subtypes (e.g. micropapillary carcinoma), the HER2 gene may be amplified but IHC reveals incomplete (Ushaped) staining. In these rare cases, incomplete stain ing as an exception from the rule has to be considered as 2+, requiring additional testing. With regard to the latter aspect, the AGO Breast Commit tee did not follow the published consensus, which does not require completeness of membrane staining as a 2+ criterion anymore. In fact, the AGO considers it more appropriate to exemplify the rare exceptions in which the HER2 gene might be amplified despite incomplete membrane staining, namely micropapillary carcinoma. Thus, reflex ISH should be done -when the traditional Food and Drug Administration (FDA)accepted 2+ criteria are met, -in those rare cases with incomplete moderatetostrong membrane staining of special histological types, and -in tumors with strong and complete staining in < 10% of cells. Otherwise, many of the former IHC 1+ cases with weak/moderate incomplete staining would be analyzed by ISH, unnecessarily increasing the costs for diagnostic HER2 testing [29] . Ki67 is helpful in determining the grade of tumors. Grade 1 (G1) tumors usually show a Ki67 index below 15% and G3 tumors exhibit a labeling index ≥ 25%. In core biopsies, Ki67 is better suited to predict the final histological grade than mitotic counts. There are a number of studies stating that a threshold of 20% is able to discriminate between the luminal A and B types, but further confirmation should be awaited. Reproducibility and interest and interlaboratory variation of testing are important issues if the Ki67 growth index is deter mined and utilized for clinical decisionmaking
Prognostic and Predictive Factors
The AGO Breast Committee acknowledges that 2 kinds of criteria for the validation and grading of evidence regarding clinical significance are valid for prognostic and predictive factors: (1) the Oxford LoE (LoEOx2001) criteria and the heterogeneity. The accurate pathological identification and classification of lesions with atypical proliferation is important to assess the individual risk of the patient, and to decide if the lesion should be excised. The recognition of atypical epi thelial proliferation is based on the distinction of hyperplastic from neoplastic lesions, i.e. on the identification of a clonal process.
General recommendations for all types of B3 lesions iden tified at core biopsy include that careful attention must be paid to the pathologicradiologic correlation for guidance of the clinical management. This is typically achieved in an inter disciplinary conference that includes the presentation of radi ologic and pathologic findings. The term 'atypical ductal hy perplasia' has been defined to describe small atypical ductal lesions with insufficient criteria for a definite diagnosis of DCIS. No change was made in the general recommendation for an excisional biopsy when ADH is identified in CNB or in a vacuumassisted biopsy specimen. FEA is a lesion with ar chitectural features of columnar cell hyperplasia with low grade nuclear atypia and is considered a precursor lesion in the lowgrade pathway. Management recommendations in corporate the actual risk of progression, which is low. Open biopsy must be considered when suspicious microcalcifica tions or a mass lesion remain radiologically detectable after core needle or vacuumassisted biopsy [37] .
With lobular intraepithelial neoplasia (LIN), several differ ent morphologic variants of lobular carcinoma in situ (LCIS) have been described to more precisely evaluate the individual risk. Pleomorphic and florid LCIS (pLCIS and fLCIS) differ from classical LCIS (cLCIS). pLCIS was shown to behave more aggressively as compared to classical LN [38] . The dis tinction of pLCIS from classical LN relies on nuclear charac teristics, with pLCIS having larger, more pleomorphic nuclei with obvious nucleoli and potentially showing apocrine differ entiation, necrosis, and microcalcifications. fLCIS is another form of LIN with high risk, which may be frequently associ ated with microinvasion [39, 40] . In the grading system of LIN (LIN 1-3), pLCIS and fLCIS are categorized as the most severe grade (LIN 3) [41] .
An excisional biopsy was recommended in pLCIS or fLCIS because of an upgrade rate greater than 25% [42] or 16% [43] , but results were inconclusive with lesions of lesser extent, namely atypical lobular hyperplasia. The argument against a routine followup biopsy is that LN as the most significant pa thology usually is an incidental finding in an otherwise benign core biopsy, and if there is no other clinically or radiologically detectable lesion, it is unlikely that an excisional biopsy could yield anything more significant [44] . This argument has to be taken seriously, and at least all cases with LCIS and a mass lesion should be followed up by a surgical biopsy. However, because of the reported upgrade rates in fully developed LCIS, the nature of these lesions as nonobligate precursors, and the risk of missing a radiologically occult invasive cancer, an open biopsy in classical LCIS should also be considered as GR, which are used throughout the guidelines, and (2) the GR as well as the modified LoE criteria for use in archived specimens (LoE2009) and in the category of tumor marker study (CTS) [30] . It needs to be emphasized that the 2 evi dence levels cannot be directly compared. In particular, the prospectively planned retrospective validation of a biomarker may be severely biased by the number of samples available for biomarker analysis from the original trial. Since the opti mal percentage of samples needed has not yet been deter mined, the AGO commission reports the original percentages in their slide set so that the readers can draw their own con clusions about the quality of the available data.
In nodenegative breast cancer, the urokinasetype plasmi nogen activator (uPA)/plasminogen activator inhibitor1 (PAI1) enzymelinked immunosorbent assay (ELISA) (Fem telle ® ) is a recommended (LoE 1a, A, AGO +) prognostic and predictive factor for the decision regarding adjuvant chemotherapy [31] . In doubtful cases of nodenegative endo crineresponsive HER2negative tumors, a multigene assay such as Oncotype DX ® or Endopredict ® may be helpful in the decisionmaking process to opt for endocrine therapy alone versus the chemo endocrine treatment option (LoE2009 I, B, AGO +). In nodepositive patients, the use of these assays needs to be carefully discussed with the patients (LoE2009 II, B, AGO +/-) since the prospective clinical trials in this setting (Rxponder, WSGADAPT, WSGPlan B) have not yet been completed and reported.
The determination of molecular subtypes in paraffinem bedded tissue has now become available using the validated PAM50 (Prosigna ® ) assay (LoE2009 II, B, AGO +/-) [32] . Prosigna [33] and Endopredict ® [34] also provide information about late recurrences, which may be used to guide endocrine therapy for more than 5 years.
Circulating tumor cells (CTCs; Cell Search ® ) can be used only in the metastatic setting as a prognostic tool (LoE2009 I, B, AGO +) since their prognostic impact has recently been validated by an international metaanalysis [35] . They are, however, not validated for clinical decisionmaking.
Lesions of Uncertain Malignant Potential (B3) Including Atypical Ductal Hyperplasia, Flat Epithelial Atypia, and Lobular Intraepithelial Neoplasia
Lesions identified on core needle biopsy (CNB) are rou tinely classified into 5 categories according to the Bcoding system, with lesions of uncertain malignant potential being grouped into the B3 category [36] . The B3 category comprises a heterogeneous group of lesions that share an increased and rate than previously reported. Only safety data have been published as yet and no grade 4 or 5 toxicity has been ob served. Nevertheless, there is no indication for trastuzumab in DCIS (LoE 5, D, AGO -/-) [58] . More data from this trial will be awaited.
Breast Cancer Surgery -Oncological Aspects
Axillary lymph node involvement is a strong prognostic marker, and in the absence of reliable imaging systems to as sess the nodal status, axillary lymph node dissection (ALND) remained the best staging tool. When axillary sentinel lymph node biopsy (SLNB) was introduced, a less radical surgical treatment evolved, with a remarkable reduction in postopera tive morbidity. Today, axillary dissection is mainly a diagnos tic procedure and improves clinical outcome only in patients with lymph node metastases. Removal of tumorfree lymph nodes increases morbidity and has no prognostic impact. Available evidence suggests that qualityassured SLNB is a reliable predictor of axillary lymph node status, with high levels of sensitivity (90-95%), specificity (100%), NPV (95%), and accuracy (97%) [59] .
The systemic treatment in patients who undergo neoadju vant therapy is generally predefined. In these patients, the histopathological response to chemotherapy (which includes response in the breast and the lymph nodes) is an important prognostic factor with significant potential to tailor future sys temic and regional treatment decisions. Therefore, it would seem more reasonable to perform SLNB after NACT in order to provide this important prognostic factor. SLNB after NACT is, however, associated with less favora ble success rates (detection rate, falsenegative rate) com pared to SLNB in primary surgery, as shown in the SENTINA trial. This relates especially to patients, who present initially with positive lymph nodes and convert to a negative axillary status under NACT. For patients with initially negative lymph nodes, the success rates for SLNB after NACT appear more favorable, although evidence from sufficiently powered pro spective trials is still lacking. Furthermore, no data regarding oncologic endpoints (diseasefree survival, overall survival) are yet available for the SLN procedure after NACT.
Patients with a positive axillary finding before NACT may have a diagnostic core needle or fineneedle biopsy to confirm axillary involvement cytologically/histologically prior to initiating chemotherapy. Proven axillary lymph node in volvement (needle biopsy or sentinel node biopsy) is an indi cation for ALND following NACT. One option is sentinel lymph node dissection after NACT, with a minimum of 3 sen tinel lymph nodes (falsenegative rate < 10%; American Col lege of Surgeons Oncology Group (ACOSOG) Z1071 trial) [60, 61] .
In case of positive SLNB before NACT ( fig. 1 ), ALND may be omitted under certain conditions (tumor < 5 cm, cN0, an option [45] , especially if multiple lobules are involved [46] [47] [48] .
Ductal Carcinoma in Situ
In addition to invasive breast cancer, the estimated annual incidence of in situ breast cancer in the USA for 2013 was 64,640. Of these, approximately 85% will be DCIS cases. The in situ breast cancer incidence rates increased by 2.8% per year from 2005 to 2009 [49] . Due to the screening programs, breast cancer is detected at earlier stages, with the detection of nonpalpable lesions and in situ carcinomas having in creased up to approximately 20% of the newly diagnosed pri mary cases [50] .
For successful BCS, the primary lesion has to be removed with a surrounding rim of healthy tissue of at least 2 mm. The challenge is to achieve clear margins in 1 surgical session. In general, positive margins indicate a reexcision procedure. Because of insufficient intraoperative assessment of the lesion extension, the reexcision rates for DCIS reported in the ma jority of studies are high, ranging from 31 to 46% for DCIS only [51] [52] [53] [54] . In contrast to invasive breast cancer there are just a very few possibilities to intraoperatively assess the spec imen margin (touch prep cytology, spectroscopy) and to lower the reoperation rate. Ahmed and Douek [55] published a sys tematic review and metaanalysis to evaluate the impact of intraoperative US (IOUS) in comparison to wireguided lo calization (WGL) in nonpalpable breast cancers and DCIS. The authors concluded that, compared with WGL, IOUS re duced the involved surgical margin rates in nonpalpable le sions as long as they were visible. Therefore, for invisible DCIS, IOUS cannot be recommended (LoE 2b, B, AGO +/-).
Radiotherapy to the breast in BCT reduces local recur rences by 50% but is not associated with a survival benefit. Since no subgroup of patients has been defined so far not to benefit from radiotherapy (with respect to local control), radiotherapy should be offered to all patients with BCT. RT can be omitted in selected patients with a minimal absolute risk of recurrence provided shared decisionmaking and careful information of the patient regarding risks and benefit is provided. This was repeatedly confirmed by a Cochrane analysis of postoperative radiotherapy for DCIS of the breast (LoE 1a, A, AGO ++) [56] . A multigene assay called DCIS Score ® showed promising data to classify patients into 3 dis tinct risk groups (low, intermediate, high). This test may be able to verify a group of patients with low risk in which radio therapy can be avoided in the future [57] .
HER2positive DCIS patients were included in the Na tional Surgical Adjuvant Breast and Bowel Project (NSABP) B43 trial, which investigates the impact of trastuzumab given concurrently with radiation therapy to radiation therapy alone. This trial is now fully recruited. Surprisingly, only 34.9% of the patients were HER2 positive (1,969), a lower reconstruction by implants. Skinsparing mastectomy (SSM) or nipplesparing mastectomy (NSM) are safe and afford a higher quality of life (LoE 2b, B, AGO ++) [63] . The preser vation of the nippleareola complex (NAC) can be performed under special conditions (LoE 2B, B, AGO ++). SSM with preservation of the NAC is also feasible after mastopexy or reduction mammoplasty (LoE 4, C, AGO ++) [64] .
If radiotherapy is indicated, the use of implants is possible regarding oncologic safety (LoE 2a, B, AGO +/-). Patients should be informed in detail about higher complication rates and poorer cosmetic results.
Synthetic meshes or acellular dermal matrices (ADM) are possible options for muscle fixation in case of immediate re construction (LoE 2b, C, AGO +). The use of ADM presents no significant increase of longterm complication rates and less capsular contracture compared to 2stage expander/im plant reconstruction without ADM (LoE 2b, C) [65] . Syn thetic meshes can be used in patients undergoing reconstruc tion after SSM or NSM with wellpreserved skin softtissue proportions and in patients with primary or secondary pro phylactic subcutaneous mastectomy; they seem to be a helpful tool for implant stabilization in terms of lateral stabilization and fixation of the musculus pectoralis major [66] .
The use of lipomodeling by autologous fat transfer is in creasing, offering an additional tool to refine breastrecon structive surgery [67] . There are reported concerns that the injection of fat may be involved in tumorigenesis by stimulat ing angiogenesis and cell growth and thus dormant cancer cells [68] . Lipofilling has already been performed for breast reconstruction in over 2,000 patients in published trials. Until now, there has been no report of increasing risk of local events or metastasis in the followup of invasive breast cancer patients [69] . By this, lipofilling can be offered and performed after mastectomy and implantbased reconstruction (LoE 2a, B, AGO +). However, lipofilling presented an increased risk of local events in subgroups of women younger than 50 years with highgrade neoplasia and Ki67 > 14% [70] . This option should be considered carefully in these subgroups.
After BCS, lipofilling should only be performed on an indi vidual basis and after detailed informed consent, due to lack of data (LoE 4, D, AGO +/-). A longer interval after diagno sis should be considered [71] .
If implant reconstruction is not suitable, pedicled (LoE 3b, C, AGO +) or free tissue flaps (LoE 3b, B, AGO +/-) can be considered. Comparing both techniques, the free tissue trans fer is a time and personnelconsuming microsurgical proce dure associated with a higher rate of reoperations, a higher total failure rate, and no higher patient satisfaction in multi variate analyses. In case of transverse rectus abdominis mus cle (TRAM) flaps, a delayed procedure should be performed in risk patients (LoE 3a, B, AGO +). Moreover, the ipsilateral pedicled TRAM is recommended (LoE 3b, A, AGO +).
Riskreducing bilateral mastectomy in healthy women (RRBM -former prophylactic mastectomy) can achieve a less than 3 lymph nodes affected, no extracapsular spread, planned whole breast irradiation for BCS, planned adequate systemic therapy (ACOSOG Z011 trial) following informed consent). In case of positive SLNB after NACT, prospective data to avoid axillary dissection are lacking and must be taken into consideration in planning axillary surgical procedures under neoadjuvant treatment conditions.
In conclusion, SLNB prior to NACT is a safe procedure that can spare many patients with advanced tumors an axillary dissection. SLNB after NACT is an important development that should, however, be performed within clinical trials to provide the necessary and urgently awaited data on clinical outcome.
Axillary dissection and radiotherapy are both associated with excellent regional control rates in clinically nodenega tive patients with a positive sentinel lymph node as shown in the AMAROS trial (LoE 1b, B, AGO +/-) [62] . Patients who received radiotherapy had significantly less arm morbidity compared to patients who underwent axillary dissection. However, many questions remain, such as the necessity of internal and suprainfra node irradiation; thus, publication of the full paper of the AMAROS trial should be awaited before radiotherapy is used routinely to replace axillary surgery in patients who require axillary dissection.
Oncoplastic and Reconstructive Surgery
Oncoplastic surgery in its original form began as combining lumpectomy or quadrantectomy with local or regional tissue rearrangement, so that the breast should be conserved and re shaped to avoid significant deformity. Oncoplastic techniques should be used in BCS in case of an expected breast volume loss > 10-20%; a wider clear margin and a lower reexcision rate can be achieved. If BCS is not possible, breast reconstruc tion should be offered to the patients. The first choice is the [75] . Treatment with these drugs is associated with a lower risk of venous thromboembo lism (VTE) and secondary cancers like endometrium cancer. The remarkable efficacy of this option could be demonstrated 10 years ago in the Canadian MA.17 trial (LoE 2b, B, AGO +) [75] . At present there are no clear data as to which of the 2 options of EAT might be the treatment of choice. It is of importance to understand that EAT is not recommended in the first 5 years after a sequence treatment.
Adjuvant Cytotoxic and Targeted Therapy
Systemic treatment is generally recommended according to the specific subtypes of breast cancer. In patients with hor mone receptorpositive, HER2negative and lowrisk biology, endocrine therapy without chemotherapy is recommended.
In patients with hormone receptorpositive, HER2nega tive and highrisk situation, conventionally dosed anthra cycline/taxanebased chemotherapy is the first choice, fol lowed by endocrine therapy. In patients with HER2over expressing tumors, sequential anthracycline/taxanebased regimens with concurrent taxane and trastuzumab are recom mended; another choice is an anthracyclinefree, carboplatin containing regimen. In patients with triplenegative breast cancer (TNBC), conventionally dosed anthracycline/taxane based chemotherapy is the first choice.
We agreed on considering the neoadjuvant approach in all patients with an indication for adjuvant chemotherapy, mainly based on tumor biology.
Based on data from the Italian Grupo Italiano Mamella (GIM) study presented by Cognetti et al. [76] at the San Antonio Breast Cancer Symposium (SABCS) 2013, epi rubi cin/cyclophosphamide (EC) followed by paclitaxel is equally effective to EC plus 5fluorouracil (FEC) followed by pacli taxel. Therefore, our new guideline recommendation is EC without the addition of 5fluorouracil. The best combinations are either EC 90/600 q3w × 4 followed by paclitaxel 80 qw × 12 or docetaxel 75, adriamycin 50, cyclophosphamide 600 q3w × 6 (TAC). Sequential regimens like 4 × adriamycin/cyclophos phamide (AC) q3w followed by docetaxel 100 q3w × 4 or FEC q3w × 3 followed by docetaxel q3w × 3 are also feasible.
For dosedense regimens, additional knowledge has accu mulated in the year 2014: -The Italian GIM study presented by Cognetti et al. [76] has shown that EC 90/600 q2w with pegfilgrastim followed by paclitaxel 175 q2w is superior to the same regimen applied at 3weekly intervals. -The NSABP B38 trial published by Swain et al. [77] has shown that 6 cycles of TAC is equally effective to dose dense EC followed by paclitaxel q2w.
reduction in breast cancer incidence (LoE 1b, A, AGO ++). It may be offered to patients with a BRCA1/2 mutation (LoE 2a, B, AGO +) or in highrisk women (i.e. with a lifetime risk ≥ 30% or a heterozygote risk ≥ 20%) (LoE 3a, C, AGO +/-). Possible techniques are simple mastectomy, SSM, and NSM (NAC sparing) (LoE 2b, C, AGO +). Actual data present a high need for education of physicians -especially in Germany -regarding the indications, possibilities, and advantages of RRBM (LoE 1b, A, AGO ++) [72] .
Adjuvant Endocrine Therapy
Adjuvant endocrine therapy represents the most important therapeutic option in the treatment of early breast cancer. As endocrine therapy represents a targeted treatment option, a basic requirement is the proof of endocrine sensitivity (ES). ES by definition requires that at least 1% of the tumor cells should stain positive for either estrogen or progesterone re ceptors. In premenopausal women, 5year treatment with tamoxifen is the standard regimen. In special cases (e.g. marked formation of ovarian cysts), suppression of the ova ries with gonadotropinreleasing hormone (GnRH) analogs may be useful. In postmenopausal patients, there are 3 treat ment options available for the duration of 5 years: -5 years of tamoxifen, -5 years of aromatase inhibition or -a sequence therapy with 2 years of tamoxifen followed by an aromatase inhibitor for 3 years or 2 years with an aro matase inhibitor followed by 3 years of tamoxifen. This treatment is associated with the best therapeutic index for these patients. When lobular breast cancer occurs, upfront therapy using an aromatase inhibitor might be beneficial. However, these data have only been presented at conferences and have not yet been fully published. In recent years, the importance of extended adjuvant therapy has been increasingly discussed. The ATLAS trial [73] and the aTTom [74] study referred to the benefit of extended endocrine therapy with tamoxifen beyond 5 years (LoE 1a, A, AGO ++). Both studies reported a reduction in breast cancerrelated mortality of 1.9%. How ever, this reduction in tumorrelated mortality was associated with an increase in treatmentrelated mortality, when consid ered over the entire study. This increase was equal to the breast cancerrelated mortality reduction.
The reduction in breast cancerrelated mortality was in duced by the reduction of intramammary recurrence and was attributed to the reduction of secondary cancers. It is there fore a tertiary preventive approach, by nature. Thus, this extended adjuvant therapy should be offered only to women who have an increased locoregional risk of recurrence or an increased risk of a second breast cancer.
For premenopausal women, in these cases, 10year tamox ifen therapy is an option to reduce their overall risks. In post response after 2 cycles of DAC in hormone receptorpositive breast cancer, a total of 8 instead of 6 cycles of DAC may be considered (LoE 2b, C, AGO +). In the case of no response after 2 cycles of DAC, continuation of neoadjuvant systemic therapy with a noncrossresistant regimen, such as 4 × vino rel bine/capecitabine (NX) may be beneficial (LoE 2b, B, AGO +). This can be an option in individual cases but cannot be considered a routine approach.
With respect to endocrine neoadjuvant therapy, in excep tional situations endocrine treatment with luteinizing hor monereleasing hormone (LHRH) plus aromatase inhibitor may be considered for premenopausal women (LoE 1b, C, AGO +/-).
New predictive factors, such as tumor cell infiltration/ lymphocytepredominant breast cancer or phosphatidylino sitol4,5bisphosphate 3kinase catalytic subunit alpha (PIK3CA) mutation in the tumor, are promising tools but not yet applicable in the routine clinical setting (LoE II, B, AGO +).
The indications for mastectomy after NACT remain un changed: positive margins after repeated excisions (LoE 3b, C, AGO ++), radiotherapy not feasible (LoE 5, D, AGO ++), and inflammatory breast cancer in the case of only clinical complete response (LoE 2b, C, AGO +). In inflammatory breast cancer with pCR after NACT, BCS may be discussed with the patient (AGO +/-) as an individual option, with men tioning of the scarce database for such an approach.
Similarly, large tumors (cT4a-c) are only a relative indica tion for mastectomy after NACT (AGO +/-). Multicentric lesions should be exactly defined (bicentric, tricentric), and the remaining tumor load after NACT must be set in relation to the breast size (AGO +/-).
Postneoadjuvant concepts are currently investigated in clinical trials. There is no indication for further chemotherapy in case of no pCR.
Adjuvant Radiotherapy
Due to new results published 2013 from metaanalyses and prospective randomized clinical trials regarding radioonco logical aspects, the AGO Breast Committee has reevaluated some current issues relevant to clinical practice.
There is no subgroup -including elderly patients -without any benefit of normofractionated (nf) radiotherapy (RT) after BCS of DCIS and invasive cancer in terms of significant increase of local/locoregional tumor control resulting in a ++ recommendation of the AGO. However, for elderly patients there is no impact of postoperative radiotherapy on breast cancerrelated survival. There are more severe cardiovascular events after radiotherapy of the breast [56, [85] [86] [87] [88] [89] .
Regarding the role of (accelerated) partial breast irradia tion/intraoperative (electron) radiotherapy (IO(E)RT) after BCS as sole radiotherapy modality, the prospective rand -The Southwest Oncology Group (SWOG) S0221 study presented by Budd et al. [78] at the ASCO meeting 2013 has shown that paclitaxel 175 q2w × 6 is equally effective to paclitaxel 80 mg/m 2 weekly × 12. -Therefore, the general consideration for anthracycline/ taxane treatment in the adjuvant setting would be opti mally 4 × EC followed by 12 × paclitaxel qw [79] . -At the moment, it cannot be decided whether this regimen or the German dosedense, doseintensified regimen ETC (epirubicin, paclitaxel, cyclophosphamide) are equally ef fective [80] . -The answer to this question will possibly be given by the mature results of the German Adjuvant Intergroup Node positive (GAIN, ETC vs. EC followed by paclitaxel + capecitabine) study.
Adjuvant Treatment for Patients with HER2-Positive Tumors
For the adjuvant therapy of patients with HER2over expressing tumors, trastuzumab is recommended for the duration of 1 year in patients with nodepositive disease and also in patients with nodenegative disease if the tumor has a diameter of more than 10 mm [81] [82] [83] .
In patients with a tumor diameter between 5 and 10 mm, we also recommend the use of chemotherapy plus trastu zumab. In patients with a tumor diameter of < 5 mm, an indi vidual discussion with the patient should be performed in order to decide on whether to treat with chemotherapy and trastuzumab. In the study presented by Tolaney et al. [84] at the SABCS 2013, chemotherapy was performed with 12 weeks of weekly paclitaxel with the addition of trastuzumab followed by trastuzumab in patients with tumors of less than 3 cm in diameter and no involved axillary nodes. The 5year outcome of these patients was excellent; we therefore recom mend such a regimen in individual cases based on discussions with the patients [84] . This is a highly feasible regimen in post menopausal patients with additional comorbidities and pT1 N0 situation.
Neoadjuvant Chemotherapy
NACT is indicated in every case with an indication for adjuvant chemotherapy (LoE 1b, A, AGO +). In particular, in patient subgroups where a pCR is associated with improved survival, such as in triplenegative and HER2positive can cers, NACT (plus targeted therapy) should be the preferred therapeutic approach (AGO +). Independent of the BRCA1/2 status, a platinum saltcontaining regimen should be consid ered (LoE 2b, B, AGO +) in TNBC based on data from sev eral phase II randomized trials (e.g. GeparSixto, CALGB 40603).
Responseguided treatment has been shown to be bene ficial within the GeparTrio trial. Consequently, in case of regional relapse. For the pN0 subgroup bearing more than 1 risk factor, PMRT is considered to complete treatment in these patients. Now, the recent metaanalysis of Li et al. [103] covering more than 3,400 patients as well as further retrospec tive cohort analyses confirmed statistically significant benefi cial effects of PMRT even in patients with 1-3 positive lymph nodes in terms of locoregional tumor control. Therefore, PMRT should be recommended for patients with 1-3 positive lymph nodes (LoE 1a, A, AGO +) [102] [103] [104] 106] . At present, it is unclear which subgroups with indication for PMRT (high risk, pN0 or inter mediate pN1 (1-3 lymph nodes)) would benefit from an inclusion of the regional lymph nodes into the radiotherapy target. Better local control through modern systemic treatments has to be taken into consideration. Recently published studies were in their time conducted with out modern therapies as aromatase inhibitors and antiHER2 therapies were not yet available.
Complementary Treatment
Generally, the AGO recommendations tend to remain un changed. Trends seen in recent previous years are followed and some vague recommendations are being slightly consoli dated. It has become clear that the greatest danger of comple mentary and alternative medicine (CAM) is in omitting conventional therapy, specifically systemic therapy and sur gery. This could be clearly demonstrated by Saquib et al. [107] . The purpose of their study was to assess whether CAM approaches affected breast cancer prognosis in those patients who did not receive systemic therapy. They performed a secondary data analysis of baseline/survey data from the Women's Healthy Eating and Living (WHEL) study includ ing 2,562 breast cancer survivors. The mean followup ap proached 7.3 years. Those women who did not receive any systemic treatment had a higher risk for time to additional breast cancer events (hazard ratio (HR) = 1.9, 95% confi dence interval (CI) 1.32-2.73) and for allcause mortality (HR = 1.7, 95% CI 1.06-2.73) compared to those who had received systemic treatment. Among 177 women who did not receive systemic treatment, CAM use was not significantly related with additional breast cancer events. The use of dietary supplements or CAM therapies did not change this risk. This indicates that complementary and alternative therapies did not alter the outcome of breast cancer and should not be used in place of standard treatment.
New data from randomized controlled trials enhance the impact of mindbody medicine such as yoga, chigong, taichi, and hypnosis for improving sleep, fatigue, quality of life, and physical performance. Viscum album preparations improve quality of life and side effects in patients after chemotherapy. The 5year results of a placebocontrolled trial of coenzyme Q10 to relieve selfreported treatmentrelated fatigue were negative.
omized TARGIT A trial (comparing IORT with external beam radiotherapy (EBRT)) could show no significant in crease of local recurrence with riskadapted intraoperative prepathology radiotherapy with 50 kV. Riskadapted prepa thology IORT means partial breast radiation at the time of first surgery plus an additional EBRT or, in case of unex pected risk factors like postoperative lymphangiosis carcino matosa (pL1), an additional EBRT. The inclusion criteria were an age older than 45 years (in Germany, older than 50 years), no lobular invasive cancer, no extensive intraductal component (EIC, defined as the presence of intraductal carci noma both in the invasive tumor and in adjacent breast tissue that comprised >25% of the tumor), cancer < 2 cm (Ger many), and hormone receptorpositive cancer. The other ran domized trial compares IOERT with EBRT. The patients were not selected. The local recurrence rate was significantly higher with IOERT, but very low in both study arms [90] [91] [92] [93] [94] [95] [96] .
With regard to the duration of radiotherapy by appropri ately dosed hf schedules (i.e. single fractions of 2.66 Gy, re striction of total dose to 39-41.6 Gy), the recently published 10year followup data of the UK START A/B and the Cana dian trials were considered to indicate safety and effectivity. Consequently, the British National Institute for Health and Clinical Excellence (NICE) confirmed this approach as the new standard and recommended UK START BhfRT in its guidelines [97] [98] [99] [100] . Out of all these trials dealing with hf radiotherapy schedules, only the UK START B trial could also demonstrate a minimal but statistically significant overall survival benefit [97] . Based on these results, the AGO Breast Committee members now opted ++ (LoE 1a, A, AGO ++) in favor of hf as compared to + (LoE 1a, A, AGO +) for nf schedules. This vote disagrees with the recommendations regarding hf concepts from the updated German Society of Radiation Oncology (DEGRO) practical guidelines 2013/14 [101] .
A tumor bed boost radiotherapy as part of a wholebreast irradiation (WBI) concept is as well as feasibility in hf regi mens. In addition to WBI it reduces local recurrence in all age groups and should therefore be offered to patients who ap pear biologically and mentally fit enough to experience the benefit of improved local control. Results of ongoing clinical trials evaluating different boost concepts (e.g., simultaneously integrated boost (SIB), anticipated boost applying IO(E)RT prior to WBI) and within nf and hf concepts are expected.
A metaanalysis and further data from randomized con trolled trials have improved the evidence levels indicating postmastectomy irradiation (PMRT) [102] [103] [104] [105] . PMRT is beneficial for all patients with 'highrisk' criteria in terms of both locoregional tumor control and overall survival. How ever, it is still a matter of debate if this is most likely also true for patients with 'intermediaterisk' criteria (i.e. relapse risk (RR) 10-20%; T1-2 and N+(1-3), G3, vascular invasion, lobular subtype; > T2 N0). In pN0 patients, recommendation for PMRT depends on the number of risk factors for loco tic interventions yielding promising early results. In this context, Montero et al. [109] reported on the addition of NOV 002 (a formulation of disodium glutathione disulfide) to chem otherapy, which has been shown to increase antitumor efficacy in animal models and some earlyphase oncology trials. Con current NOV002 resulted in a pCR rate of 38% for AC → T (T = docetaxel) chemotherapy, which is higher than previously reported rates, e.g. in the B27 or the GeparDuo trials.
This and other early indications of efficacy do not at all allow general recommendation; so, all these approaches can only be recommended within the settings of properly con trolled trials.
However, one new piece of information could be ready for clinical application in difficult situations without better and more promising alternatives: the tentative treatment of skin metastases with the immunomodulator imiquimod. A pro spective case series was published by Adams et al. [110] , eval uating the local tumor response rate of breast cancer skin metastases treated with topical imiquimod, applied 5 days/ week for 8 weeks. 10 patients were enrolled. 2 patients achieved a partial response. The responders showed histologic tumor regression with evidence of an immunemediated re sponse, shown by changes in the tumor lymphocytic infiltrate and locally produced cytokines.
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Quite a bit of new information has accumulated on immu notherapeutic approaches. Most modalities do not boast high evidence levels and rather represent early exploratory trials, however indicating that this enigmatic field holds future promise. The danger in these methods is that patients are prone to fraudulent offers from 'immunotherapists' and 'heal ers' claiming that boosting the immune system will cure early and progressive disease, as the blackbox promise of immuno therapy is attractive and seemingly selfexplanatory for dis traught patients.
Recently, the discovery that chronic inflammation in the tumor microenvironment promotes tumor growth and survival during different stages of breast cancer development has led to the development of novel immunotherapies. Several immu notherapeutic strategies have been studied both preclinically and clinically and have already been shown to enhance the ef ficacy of conventional treatment modalities. Therefore, thera pies targeting the immune system may represent a promising nextgeneration approach for the treatment of breast cancers.
Dendritic Cell Intradermal Vaccination
In a recent paper from China [108] , dendritic cell (DC) vaccines were generated from CD14+ precursors pulsed with autologous tumor lysates. DCs were matured with defined factors that induced surface marker and cytokine production. Individuals were immunized intradermally 4 times. Overall survival and disease progression rates were compared with those of contemporaneous patients who did not receive DC vaccines. There was no difference in overall survival between the patients with and without DC vaccine administration. The 3year progressionfree survival was significantly prolonged: 76.9% versus 31.0% (with vs. without DC vaccine, p < 0.05). The authors concluded that their findings strongly suggest that tumor lysatepulsed DCs provide a standardized and widely applicable source of breast cancer antigens that are very effective in evoking antibreast cancer immune responses.
Recently, quite a number of preliminary clinical trials have been evaluated and published reporting on immunotherapeu 
